Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Intensive Care
Published in: Annals of Intensive Care 1/2017

Open Access 01-12-2017 | Review

Piperacillin–tazobactam as alternative to carbapenems for ICU patients

Authors: Benoit Pilmis, Vincent Jullien, Alexis Tabah, Jean-Ralph Zahar, Christian Brun-Buisson

Published in: Annals of Intensive Care | Issue 1/2017

Login to get access

Abstract

Several studies suggest that alternatives to carbapenems, and particulary beta-lactam/beta-lactamase inhibitor combinations, can be used for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE)-related infections in non-ICU patients. Little is known concerning ICU patients in whom achieving the desired plasmatic pharmacokinetic/pharmacodynamic (PK/PD) target may be difficult. Also, in vitro susceptibility to beta-lactamase inhibitors might not translate into clinical efficacy. We reviewed the recent clinical studies examining the use of BL/BLI as alternatives to carbapenems for therapy of bloodstream infection, PK/PD data and discuss potential ecological benefit from avoiding the use of carbapenems. With the lack of prospective randomized studies, treating ICU patients with ESBL-PE-related infections using piperacillin–tazobactam should be done with caution. Current data suggest that BL/BLI empirical use should be avoided for therapy of ESBL-PE-related infection. Also, definitive therapy should be reserved to patients in clinical stable condition, after microbial documentation and results of susceptibility tests. Optimization of administration and higher dosage should be used in order to reach pharmacological targets.
Literature
1.
Arpin C, Quentin C, Grobost F, Cambau E, Robert J, Dubois V, et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing enterobacteriaceae in the French community setting. J Antimicrob Chemother. 2009;63:1205–14.PubMedCrossRef
2.
Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333–40.PubMedCrossRef
3.
Prinapori R, Guinaud J, Khalil A, Lecuyer H, Gendrel D, Lortholary O, et al. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae. Am J Infect Control. 2013;41:259–60.PubMedCrossRef
4.
Barbier F, Pommier C, Essaied W, Garrouste-Orgeas M, Schwebel C, Ruckly S, et al. Colonization and infection with extended-spectrum β-lactamase-producing enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure? J Antimicrob Chemother. 2016;71:1088–97.PubMedCrossRef
5.
6.
Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013;57:1488–95.PubMedPubMedCentralCrossRef
7.
Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, et al. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;62:1009–17.CrossRef
8.
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with Hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016;63:e61–111.PubMedPubMedCentralCrossRef
9.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43:304–77.PubMedCrossRef
10.
Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2000;6:460–3.
11.
Piroth L, Aubé H, Doise JM, Vincent-Martin M. Spread of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae: are beta-lactamase inhibitors of therapeutic value? Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 1998;27:76–80.CrossRef
12.
Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á. Extended-Spectrum Beta-Lactamases—Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54:167–74.CrossRef
13.
Ng TM, Khong WX, Harris PNA, De PP, Chow A, Tambyah PA, et al. Empiric piperacillin–tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing enterobacteriaceae. PLOS ONE. 2016;11:e0153696.PubMedPubMedCentralCrossRef
14.
15.
16.
Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 2002;28:1718–23.PubMedCrossRef
17.
Kang C-I, Kim S-H, Park WB, Lee K-D, Kim H-B, Kim E-C, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004;48:4574–81.PubMedPubMedCentralCrossRef
18.
Wang R, Cosgrove SE, Tschudin-Sutter S, Han JH, Turnbull AE, Hsu AJ, et al. Cefepime therapy for cefepime-susceptible extended-spectrum β-lactamase-producing enterobacteriaceae bacteremia. Open Forum Infect Dis. 2016;3:ofw132.PubMedPubMedCentralCrossRef
19.
Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, et al. Carbapenem therapy is associated with improved survival compared with piperacillin–tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60:1319–25.
20.
Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, et al. Carbapenems versus piperacillin–tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing enterobacteriaceae. Infect Control Hosp Epidemiol. 2015;36:981–5.PubMedCrossRef
21.
Lee C-C, Lee N-Y, Yan J-J, Lee H-C, Chen P-L, Chang C-M, et al. Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy. Antimicrob Agents Chemother. 2010;54:3551–6.PubMedPubMedCentralCrossRef
22.
Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15:475–85.PubMedCrossRef
23.
Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Piperacillin penetration into tissue of critically ill patients with sepsis—bolus versus continuous administration? Crit Care Med. 2009;37:926–33.PubMedCrossRef
24.
Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, Gomersall C, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56:236–44.CrossRef
25.
Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142–50.PubMedCrossRef
26.
Carlier M, Noë M, De Waele JJ, Stove V, Verstraete AG, Lipman J, et al. Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. J Antimicrob Chemother. 2013;68:2600–8.PubMedCrossRef
27.
Wu N, Chen BY, Tian SF, Chu YZ. The inoculum effect of antibiotics against CTX-M-extended-spectrum β-lactamase-producing Escherichia coli. Ann Clin Microbiol Antimicrob. 2014;13:45.PubMedPubMedCentral
28.
Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF. Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010–2014. Diagn Microbiol Infect Dis. 2016;85:459–65.PubMedCrossRef
29.
Jean S-S, Coombs G, Ling T, Balaji V, Rodrigues C, Mikamo H, et al. Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010–2013. Int J Antimicrob Agents. 2016;47:328–34.PubMedCrossRef
30.
Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009–2012. Int J Antimicrob Agents. 2014;43:328–34.PubMedCrossRef
31.
Lodise TP, Lomaestro B, Drusano GL. Piperacillin–tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007;44:357–63.CrossRef
32.
Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36:332–9.PubMedCrossRef
33.
Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, et al. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy. 2014;34:28–35.PubMedCrossRef
34.
De Waele JJ, De Neve N. Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring. Minerva Anestesiol. 2014;80:1135–42.PubMed
35.
De Waele JJ, Carrette S, Carlier M, Stove V, Boelens J, Claeys G, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40:380–7.PubMedCrossRef
36.
Felton TW, McCalman K, Malagon I, Isalska B, Whalley S, Goodwin J, et al. Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Clin Pharmacol Ther. 2014;96:438–48.PubMedPubMedCentralCrossRef
37.
McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–51.PubMedCrossRef
38.
Sádaba B, Azanza JR, Campanero MA, García-Quetglas E. Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2004;10:990–8.
39.
Felton TW, Roberts JA, Lodise TP, Van Guilder M, Boselli E, Neely MN, et al. Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother. 2014;58:4094–102.PubMedPubMedCentralCrossRef
40.
Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining antibiotic levels in intensive care unit patients (DALI) cohort. J Antimicrob Chemother. 2016;71:196–207.PubMedCrossRef
41.
Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, Fernández J, Vaquer S, Rodríguez A, et al. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. J Antimicrob Chemother. 2016;71:1651–9.PubMedCrossRef
42.
Shotwell MS, Nesbitt R, Madonia PN, Gould ER, Connor MJ, Salem C, et al. Pharmacokinetics and pharmacodynamics of extended infusion versus short infusion piperacillin–tazobactam in critically ill patients undergoing CRRT. CJASN. 2016;11:1377–83.PubMedPubMedCentralCrossRef
43.
Connor MJ, Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, et al. Therapeutic drug monitoring of piperacillin–tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2011;55:557–60.PubMedCrossRef
44.
Thompson MI, Russo ME, Matsen JM, Atkin-Thor E. Piperacillin pharmacokinetics in subjects with chronic renal failure. Antimicrob Agents Chemother. 1981;19:450–3.PubMedPubMedCentralCrossRef
45.
Giron JA, Meyers BR, Hirschman SZ, Srulevitch E. Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis. Antimicrob Agents Chemother. 1981;19:279–83.PubMedPubMedCentralCrossRef
46.
Francke EL, Appel GB, Neu HC. Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. Antimicrob Agents Chemother. 1979;16:788–91.PubMedPubMedCentralCrossRef
47.
Guet-Revillet H, Emirian A, Groh M, Nebbad-Lechani B, Weiss E, Join-Lambert O, et al. Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2014;58:4899–901.PubMedPubMedCentralCrossRef
48.
Vincent J-L, Bassetti M, François B, Karam G, Chastre J, Torres A, et al. Advances in antibiotic therapy in the critically ill. Crit Care Lond Engl. 2016;20:133.CrossRef
49.
Laterre P-F, Wittebole X, Van de Velde S, Muller AE, Mouton JW, Carryn S, et al. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. J Antimicrob Chemother. 2015;70:891–8.PubMedCrossRef
50.
Chopra T, Marchaim D, Veltman J, Johnson P, Zhao JJ, Tansek R, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2012;56:3936–42.PubMedPubMedCentralCrossRef
51.
Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, et al. β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infections due to extended-spectrum β-lactamase-producing enterobacteriaceae: a multinational, pre-registered cohort study. Antimicrob Agents Chemother. 2016;11:AAC-00365.
52.
Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2008;29:671–4.PubMedCrossRef
53.
Lee C-H, Su L-H, Tang Y-F, Liu J-W. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother. 2006;58:1074–7.PubMedCrossRef
54.
Lee N-Y, Lee C-C, Huang W-H, Tsui K-C, Hsueh P-R, Ko W-C. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing enterobacteriaceae: MIC matters. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56:488–95.CrossRef
55.
Paterson DL, Ko W-C, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis Off Publ Infect Dis Soc Am. 2004;39:31–7.CrossRef
56.
Nord CE, Heimdahl A, Kager L, Malmborg AS. The impact of different antimicrobial agents on the normal gastrointestinal microflora of humans. Rev Infect Dis. 1984;6(Suppl 1):S270–5.PubMedCrossRef
57.
Perez F, Pultz MJ, Endimiani A, Bonomo RA, Donskey CJ. Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2011;55:2585–9.PubMedPubMedCentralCrossRef
58.
Efe Iris N, Sayıner H, Yildirmak T, Simsek F, Arat ME. Vancomycin-resistant Enterococcus carrier status in the reanimation units and related risk factors. Am J Infect Control. 2013;41:261–2.PubMedCrossRef
59.
Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin Infect Dis Off Publ Infect Dis Soc Am. 2006;43(Suppl 2):S62–9.CrossRef
60.
Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–5.PubMedPubMedCentralCrossRef
61.
Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028–33.PubMedCrossRef
62.
Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2016;35:1679–89.CrossRef
63.
Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;60:1124–30.PubMedCrossRef
64.
Papadimitriou-Olivgeris M, Marangos M, Fligou F, Christofidou M, Bartzavali C, Anastassiou ED, et al. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother. 2012;67:2976–81.PubMedCrossRef
65.
Stiefel U, Pultz NJ, Donskey CJ. Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2007;51:372–5.PubMedCrossRef
66.
67.
Li H, Estabrook M, Jacoby GA, Nichols WW, Testa RT, Bush K. In vitro susceptibility of characterized β-lactamase-Producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015;59:1789–93.PubMedPubMedCentralCrossRef
68.
69.
Kang C-I, Park SY, Chung DR, Peck KR, Song J-H. Piperacillin–tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect. 2012;64:533–4.PubMedCrossRef
70.
Bloos F, Rüddel H, Thomas-Rüddel D, Schwarzkopf D, Pausch C, Harbarth S, et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. Intensive Care Med. 2017. http://​doi.​org/​10.​1007/​s00134-017-4782-4
71.
Guet-Revillet H, Tomini E, Emirian A, Join-Lambert O, Lécuyer H, Zahar J-R, et al. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing enterobacteriaceae: an in silico pharmacokinetic study. Int. J. Antimicrob Agents. 2016;49:62–6.PubMedCrossRef
72.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.PubMedPubMedCentralCrossRef
73.
Pettigrew MM, Johnson JK, Harris AD. The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance. Ann Epidemiol. 2016;26:342–7.PubMedPubMedCentralCrossRef
74.
Gharbi M, Moore LSP, Gilchrist M, Thomas CP, Bamford K, Brannigan ET, et al. Forecasting carbapenem resistance from antimicrobial consumption surveillance: lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit. Int J Antimicrob Agents. 2015;46:150–6.PubMedPubMedCentralCrossRef
75.
Plüss-Suard C, Pannatier A, Kronenberg A, Mühlemann K, Zanetti G. Impact of antibiotic use on carbapenem resistance in Pseudomonas aeruginosa: is there a role for antibiotic diversity? Antimicrob Agents Chemother. 2013;57:1709–13.PubMedPubMedCentralCrossRef
76.
Wexler HM, Finegold SM. Impact of imipenem/cilastatin therapy on normal fecal flora. Am J Med. 1985;78:41–6.PubMedCrossRef
77.
DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, et al. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin–tazobactam therapy for intraabdominal infections. Antimicrob Agents Chemother. 2005;49:3217–21.PubMedPubMedCentralCrossRef
78.
Pultz MJ, Donskey CJ. Effects of imipenem-cilastatin, ertapenem, piperacillin–tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice. Antimicrob Agents Chemother. 2007;51:3044–5.PubMedPubMedCentralCrossRef
79.
Gagliotti C, Giordani S, Ciccarese V, Barozzi A, Giovinazzi A, Pietrantonio AM, et al. Risk factors for colonization with carbapenemase-producing Klebsiella pneumoniae in hospital: a matched case-control study. Am J Infect Control. 2014;42:1006–8.PubMedCrossRef
80.
Mittal G, Gaind R, Kumar D, Kaushik G, Gupta KB, Verma PK, et al. Risk factors for fecal carriage of carbapenemase producing enterobacteriaceae among intensive care unit patients from a tertiary care center in India. BMC Microbiol. 2016;16:138.PubMedPubMedCentralCrossRef
81.
Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY, et al. Risk factors for acquisition of carbapenem resistant enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control. 2015;4:26.PubMedPubMedCentralCrossRef
82.
Jiao Y, Qin Y, Liu J, Li Q, Dong Y, Shang Y, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study. Pathog Glob Health. 2015;109:68–74.PubMedPubMedCentralCrossRef
83.
Candevir Ulu A, Kurtaran B, Inal AS, Kömür S, Kibar F, Yapıcı Çiçekdemir H, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infection: a serious threat in ICUs. Med Sci Monit Int Med J Exp Clin Res. 2015;21:219–24.
84.
Gómez Rueda V, Zuleta Tobón JJ. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study. Colomb Méd Cali Colomb. 2014;45:54–60.
85.
Ahn JY, Song JE, Kim MH, Choi H, Kim JK, Ann HW, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study. Am J Infect Control. 2014;42:621–5.PubMedCrossRef
86.
Mantzarlis K, Makris D, Manoulakas E, Karvouniaris M, Zakynthinos E. Risk factors for the first episode of Klebsiella pneumoniae resistant to carbapenems infection in critically ill patients: a prospective study. Biomed Res Int. 2013;2013:850547.PubMedPubMedCentralCrossRef
87.
Dizbay M, Guzel Tunccan O, Karasahin O, Aktas F. Emergence of carbapenem-resistant Klebsiella spp infections in a Turkish university hospital: epidemiology and risk factors. J Infect Dev Ctries. 2014;8:44–9.PubMedCrossRef
88.
Orsi GB, Bencardino A, Vena A, Carattoli A, Venditti C, Falcone M, et al. Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study. Infection. 2013;41:61–7.PubMedCrossRef
89.
Chang H-J, Hsu P-C, Yang C-C, Kuo A-J, Chia J-H, Wu T-L, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. 2011;44:125–30.PubMedCrossRef
90.
Tuon FF, Rocha JL, Toledo P, Arend LN, Dias CH, Leite TM, et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Braz J Infect Dis Off Publ Braz SocInfect Dis. 2012;16:416–9.
91.
Papadimitriou-Olivgeris M, Marangos M, Christofidou M, Fligou F, Bartzavali C, Panteli ES, et al. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. Scand J Infect Dis. 2014;46:642–8.PubMedCrossRef
92.
Maseda E, Salgado P, Anillo V, Ruiz-Carrascoso G, Gómez-Gil R, Martín-Funke C, et al. Risk factors for colonization by carbapenemase-producing enterobacteria at admission to a Surgical ICU: a retrospective study. Clin: Enferm Infecc Microbiol; 2016.
93.
Popejoy MW, Paterson DL, Cloutier D, Huntington JA, Miller B, Bliss CA, et al. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials. J Antimicrob Chemother. 2017;72:268–72.PubMedCrossRef
94.
Balakrishnan I, Awad-El-Kariem FM, Aali A, Kumari P, Mulla R, Tan B, et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2011;66:2628–31.PubMedCrossRef
95.
Bin C, Hui W, Renyuan Z, Yongzhong N, Xiuli X, Yingchun X, et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis. 2006;56:351–7.PubMedCrossRef
96.
Chaubey VP, Pitout JD, Dalton B, Ross T, Church DL, Gregson DB, et al. Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes. 2010;3:116.PubMedPubMedCentralCrossRef
97.
Chung H-C, Lai C-H, Lin J-N, Huang C-K, Liang S-H, Chen W-F, et al. Bacteremia caused by extended-spectrum-β-lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother. 2012;56:618–22.PubMedPubMedCentralCrossRef
98.
De Rosa FG, Pagani N, Fossati L, Raviolo S, Cometto C, Cavallerio P, et al. The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria. Infection. 2011;39:555–61.PubMedCrossRef
99.
Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2005;49:2598–605.PubMedPubMedCentralCrossRef
100.
Ferrández O, Grau S, Saballs P, Luque S, Terradas R, Salas E. Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms. Rev Clín Esp. 2011;211:119–26.PubMedCrossRef
101.
Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65:333–41.PubMedCrossRef
102.
Harris PNA, Yin M, Jureen R, Chew J, Ali J, Paynter S, et al. Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2015;4:14.PubMedPubMedCentralCrossRef
103.
Lee C-H, Lee Y-T, Kung C-H, Ku W-W, Kuo S-C, Chen T-L, et al. Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. J Microbiol Immunol Infect. 2015;48:269–75.PubMedCrossRef
104.
Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015;59:5107–13.PubMedPubMedCentralCrossRef
105.
Qureshi ZA, Paterson DL, Pakstis DL, Adams-Haduch JM, Sandkovsky G, Sordillo E, et al. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections. Int J Antimicrob Agents. 2011;37:26–32.PubMedCrossRef
106.
Pilmis B, Parize P, Zahar JR, Lortholary O. Alternatives to carbapenems for infections caused by ESBL-producing enterobacteriaceae. Microbiol: Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin; 2014.
107.
Retamar P, López-Cerero L, Muniain MA, Pascual Á, Rodríguez-Baño J, ESBL-REIPI/GEIH Group. Impact of the MIC of piperacillin–tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2013;57:3402–4.PubMedPubMedCentralCrossRef
108.
Tsai H-Y, Chen Y-H, Tang H-J, Huang C-C, Liao C-H, Chu F-Y, et al. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis. 2014;80:222–6.PubMedCrossRef
109.
Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987–94.PubMedPubMedCentralCrossRef
110.
Tuon FF, Bianchet LC, Penteado-Filho SR. Epidemiology of extended spectrum beta-lactamase producing enterobacter bacteremia in a brazilian hospital. Rev Soc Bras Med Trop. 2010;43:452–4.PubMedCrossRef
111.
van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63:234–41.CrossRef
Metadata
Title
Piperacillin–tazobactam as alternative to carbapenems for ICU patients
Authors
Benoit Pilmis
Vincent Jullien
Alexis Tabah
Jean-Ralph Zahar
Christian Brun-Buisson
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Annals of Intensive Care / Issue 1/2017
Electronic ISSN: 2110-5820
DOI
https://doi.org/10.1186/s13613-017-0334-x

Other articles of this Issue 1/2017

Annals of Intensive Care 1/2017 Go to the issue

Research

Low HDL levels in sepsis versus trauma patients in intensive care unit

Research

Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration

Review

Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference

Research

Prognostic implications of blood lactate concentrations after cardiac arrest: a retrospective study

Research

Venovenous extracorporeal membrane oxygenation devices-related colonisations and infections

Research

Astragaloside-IV prevents acute kidney injury and inflammation by normalizing muscular mitochondrial function associated with a nitric oxide protective mechanism in crush syndrome rats